This multinational pharmaceutical company is increasing its layout in the Chinese medicine market!

【Pharmaceutical Network Enterprise News】Recently, Boji Pharmaceutical and AstraZeneca Pharmaceutical (Chengdu) Co.
, Ltd.
"hand in hand", the two sides will work together to build a highland of traditional Chinese medicine industry, in Chengdu high-tech zone to land a new type of R & D transformation institution, and Boji Pharmaceutical will provide AstraZeneca with a number of services such as traditional Chinese medicine research and development (including pharmaceutical research, non-clinical research, clinical research, registration services, etc.
), and promote the research and development services of new Chinese medicines and the secondary development of traditional Chinese
medicines 。 According to the data, Boji Pharmaceutical is a listed company
that provides domestic and foreign pharmaceutical enterprises with "one-stop" outsourcing services (CRO+CDMO) for the whole process of drug and medical device R&D and production.
For AstraZeneca, in fact, it has long had certain experience
in the layout of traditional Chinese medicine.
It is understood that on November 2 this year, at the "2022 Western Smart Medical Industry Summit", AstraZeneca Pharmaceutical (Chengdu) Co.
, Ltd.
officially signed a strategic cooperation agreement
with Tianjin Institute of Materia Medica.
AstraZeneca Chengdu International Life Science Innovation Park mainly focuses on the inheritance of traditional Chinese medicine and providing an incubation platform and business support
for innovative enterprises.
In April, AstraZeneca's innovation base focusing on the field of traditional Chinese medicine has also officially settled in Chengdu
.
In addition, as early as 2019, AstraZeneca also signed an agreement with Luye Pharmaceutical Group to officially announce the exclusive promotion rights
of Xuezhikang capsule products in Chinese mainland.
It is reported that the cardiovascular, renal and metabolic division is one of the four major sectors of AstraZeneca's business structure in China, and the five major products in the "cardiovascular field" of AstraZeneca China's website, and the blood lipid capsule (0.
3g) ranks among them
.
In fact, in recent years, with the help of many favorable policies of the state, the inheritance and innovation of traditional Chinese medicine has entered a new stage
.
According to the "2021 China Traditional Chinese Medicine Industry Innovation and Development Briefing", in the next five years, the market size of China's traditional Chinese medicine industry will maintain a compound annual growth rate of about 14.
2% and continue to grow rapidly, and by 2025, the market size is expected to reach 5 trillion yuan
.
Under the background of the vast market space of traditional Chinese medicine and the increasingly prominent situation of "involution" of chemical drugs caused by centralized procurement, many multinational pharmaceutical companies have begun to enter the market of traditional Chinese medicine to make market breakthroughs
.
For example, Sanofi has cooperated with China Resources Sanjiu to establish Sanjiu Sanofi, it is reported that the advantages of China Resources Sanjiu in the past were mainly cold medicine and Chinese patent medicine, and since 2017, it has laid out professional markets
such as pediatrics, orthopedics, gynecology, hepatobiliary and so on.
After the cooperation with Sanofi, Sanofi's "Good Doll" will be integrated with the existing pediatric brand of CR Sanjiu
.
In addition, in 2014, Boehringer Ingelheim also reached a cooperation with Guangzhou Pharmaceutical Group to promote Pediatric Seven Star Tea Syrup
under Guangzhou Pharmaceutical Group.
Then in 2015, Boehringer Ingelheim announced that its first proprietary Chinese medicine OTC product, Lecoton, was officially launched
.
The industry believes that with the aging of the domestic population and the increase in the incidence of chronic diseases, the "prevention of diseases" of traditional Chinese medicine will bring huge domestic market demand
.
In the future, relying on their industry status, international platforms and industrial resources, multinational pharmaceutical companies are expected to help local Chinese medicine enterprises accelerate innovation and international promotion
.
In fact, AstraZeneca has said that cooperation with Chengdu High-tech Zone to build a traditional Chinese medicine innovation industry base will help AstraZeneca focus on the modernization and innovative development of traditional Chinese medicine and promote international experience exchange
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.